Nature Communications (Jun 2019)
Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
- Gerard Minuesa,
- Steven K. Albanese,
- Wei Xie,
- Yaniv Kazansky,
- Daniel Worroll,
- Arthur Chow,
- Alexandra Schurer,
- Sun-Mi Park,
- Christina Z. Rotsides,
- James Taggart,
- Andrea Rizzi,
- Levi N. Naden,
- Timothy Chou,
- Saroj Gourkanti,
- Daniel Cappel,
- Maria C. Passarelli,
- Lauren Fairchild,
- Carolina Adura,
- J. Fraser Glickman,
- Jessica Schulman,
- Christopher Famulare,
- Minal Patel,
- Joseph K. Eibl,
- Gregory M. Ross,
- Shibani Bhattacharya,
- Derek S. Tan,
- Christina S. Leslie,
- Thijs Beuming,
- Dinshaw J. Patel,
- Yehuda Goldgur,
- John D. Chodera,
- Michael G. Kharas
Affiliations
- Gerard Minuesa
- Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center
- Steven K. Albanese
- Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center
- Wei Xie
- Structural Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Yaniv Kazansky
- Weill Cornell Medical College, Tri-Institutional MD-PhD Program, Rockefeller University and Sloan Kettering Institute
- Daniel Worroll
- Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences
- Arthur Chow
- Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center
- Alexandra Schurer
- Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center
- Sun-Mi Park
- Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center
- Christina Z. Rotsides
- Chemical Biology Program, Sloan Kettering Institute and Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center
- James Taggart
- Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center
- Andrea Rizzi
- Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Levi N. Naden
- Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Timothy Chou
- Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center
- Saroj Gourkanti
- Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center
- Daniel Cappel
- Schrödinger GmbH
- Maria C. Passarelli
- Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Lauren Fairchild
- Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Carolina Adura
- High-Throughput and Spectroscopy Resource Center, The Rockefeller University
- J. Fraser Glickman
- High-Throughput and Spectroscopy Resource Center, The Rockefeller University
- Jessica Schulman
- Hematologic Oncology Tissue Bank, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Christopher Famulare
- Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Minal Patel
- Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
- Joseph K. Eibl
- Northern Ontario School of Medicine
- Gregory M. Ross
- Northern Ontario School of Medicine
- Shibani Bhattacharya
- New York Structural Biology Center, NMR Group
- Derek S. Tan
- Chemical Biology Program, Sloan Kettering Institute and Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center
- Christina S. Leslie
- Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Thijs Beuming
- Schrödinger, Inc.
- Dinshaw J. Patel
- Structural Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Yehuda Goldgur
- Structural Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- John D. Chodera
- Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Michael G. Kharas
- Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-019-10523-3
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 15
Abstract
The RNA binding protein MUSASHI-2 (MSI2) is a potential therapeutic target for acute myeloid leukemia. Here the authors identify a small molecule inhibitor of MSI2 and characterize its effects in a murine leukemia model.
